Clinical Trials Sponsored by Fore Biotherapeutics

Total 19527 results

Noveome Biotherapeutics, formerly Stemnion

Completed

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

Periodontal Disease

United States
Noveome Biotherapeutics, formerly Stemnion

Terminated

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

Diabetes | Third Degree Burns

United States
Noveome Biotherapeutics, formerly Stemnion

Completed

ST266 in UV-induced Inflammation

Skin Burns
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Korea, Republic of, Canada
Innostellar Biotherapeutics Co.,Ltd

Active, not recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Inherited Retinal Dystrophy Associated With RPE65 Mutations

China
Noveome Biotherapeutics, formerly Stemnion

Completed

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Sensei Biotherapeutics, Inc.
Accelovance

Completed

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Prostate Cancer

United States
Jennerex Biotherapeutics

Completed

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer (FLASH)

Hepatocellular Carinoma

United States, Korea, Republic of, Spain
Noveome Biotherapeutics, formerly Stemnion

Terminated

ST266 Versus Standard Care In Treating Partial Thickness Burns

Burns

United States
Noveome Biotherapeutics, formerly Stemnion

Completed

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

Radiation-induced Dermatitis

United States
Jennerex Biotherapeutics

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Melanoma | Renal Cell Carcinoma | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Canada
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Sensei Biotherapeutics, Inc.
Regeneron Pharmaceuticals

Recruiting

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Cervix Cancer | Advanced Solid Tumor | Advanced Cancer | Colon Cancer | Thyroid Cancer | Solid Tumor... and other conditions

United States
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

Cancer | Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | NSCLC | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Cancer Metastatic | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | NSCLC, Recurrent | Non Small Cell Lung Cancer Recurrent | Non-Small Cell...

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Advanced Solid Tumor

Australia, China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)

Multiple Myeloma

China
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (BASECAMP-1)

Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Pancreas Cancer | Ovarian Carcinoma | Solid Tumor, Adult | CRC | Mesothelioma; Lung

United States
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-02 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Australia, China, United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Unknown

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Solid Tumor | CAR

China
Jennerex Biotherapeutics
Green Cross Corporation

Completed

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Neoplasms, Liver

Korea, Republic of
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Affimed GmbH
Artiva Biotherapeutics, Inc.

Recruiting

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)

Peripheral T Cell Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

China, Australia
University of Pennsylvania
Northwest Biotherapeutics

Withdrawn

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cancer

United States
Noveome Biotherapeutics, formerly Stemnion
Parexel

Recruiting

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis

Necrotizing Enterocolitis

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Sonnet BioTherapeutics
Hoffmann-La Roche

Recruiting

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Advanced Solid Tumor | Platinum-resistant Ovarian Cancer

United States, Australia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Cancer Research UK
Barinthus Biotherapeutics

Suspended

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Esophageal Neoplasms | Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Yale University
Iovance Biotherapeutics, Inc.

Completed

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Allgenesis Biotherapeutics Inc.
ORA, Inc.

Completed

A Study of AG-80308 in Dry Eye Patients

Dry Eye Disease

United States
Jennerex Biotherapeutics
Transgene

Completed

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Colorectal Carcinoma | CRC

Canada, United States, France
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech

Terminated

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

Persistent Corneal Epithelial Defect

United States
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech

Completed

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Cytokine Release Syndrome

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Loma Linda University
Nitric BioTherapeutics, Inc

Terminated

Topical Nitric Oxide Trial in Chronic Non-Healing Wounds

Chronic Ulcer of Lower Extremity

United States
Bolt Biotherapeutics, Inc.
Hoffmann-La Roche

Recruiting

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

United States
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

United States, Spain, France, Korea, Republic of, Italy
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China

Clinical Trials Sponsored by Fore Biotherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations